O
Ori Elkayam
Researcher at Tel Aviv Sourasky Medical Center
Publications - 233
Citations - 7993
Ori Elkayam is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 46, co-authored 191 publications receiving 6499 citations. Previous affiliations of Ori Elkayam include Tel Aviv University.
Papers
More filters
Journal ArticleDOI
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
S. van Assen,Nancy Agmon-Levin,Ori Elkayam,Ricard Cervera,Michele F. Doran,Maxime Dougados,Paul Emery,Paul Emery,Pierre Geborek,John P. A. Ioannidis,David Jayne,Cees G. M. Kallenberg,Ulf Müller-Ladner,Yehuda Shoenfeld,Yehuda Shoenfeld,Ljudmila Stojanovich,Guido Valesini,NM Wulffraat,Marc Bijl +18 more
TL;DR: Recommendations for vaccination in patients with AIIRD based on the currently available evidence and expert opinion were formulated, and more research is needed, particularly regarding the incidence of vaccine-preventable infectious diseases and the safety of vaccination in Patients with A IIRD.
Journal ArticleDOI
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
Victoria Furer,Victoria Furer,Christien Rondaan,Marloes W Heijstek,Nancy Agmon-Levin,Nancy Agmon-Levin,Sander van Assen,Marc Bijl,F. C. Breedveld,Raffaele D'Amelio,Maxime Dougados,Meliha C Kapetanovic,Jacob M van Laar,A. De Thurah,Robert Landewé,Anna Molto,Ulf Müller-Ladner,Karen Schreiber,Leo Smolar,James T. Walker,Klaus Warnatz,Nico M Wulffraat,Ori Elkayam,Ori Elkayam +23 more
TL;DR: The updated EULAR recommendations provide an up-to-date guidance on the management of vaccinations in patients with AIIRD, favouring vaccination during quiescent disease, preferably prior to the initiation of immunosuppression.
Journal ArticleDOI
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Victoria Furer,Tali Eviatar,Devy Zisman,Hagit Peleg,Daphna Paran,David Levartovsky,Michael Zisapel,Ofir Elalouf,Ilana Kaufman,Roni Meidan,Adi Broyde,Ari Polachek,Jonathan Wollman,Ira Litinsky,Katya Meridor,Hila Nochomovitz,Adi Silberman,Dana Rosenberg,Joy Feld,Amir Haddad,Tal Gazzit,Muna Elias,Nizar Higazi,Fadi Kharouf,Gabi Shefer,Orly Sharon,Sara Pel,Sharon Nevo,Ori Elkayam +28 more
TL;DR: A multicentre observational study evaluated the immunogenicity and safety of the two-dose regimen BNT162b2 mRNA vaccine in adult patients with AIIRD compared with the general population as mentioned in this paper.
Journal ArticleDOI
Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers
Irina Fomin,Dan Caspi,Virginia Levy,Noemi Varsano,Yael Shalev,Daphna Paran,David Levartovsky,Irina Litinsky,Ilana Kaufman,Irena Wigler,Ella Mendelson,Ori Elkayam +11 more
TL;DR: Influenza virus vaccine generated a good humoral response in rheumatoid patients, although lower than in healthy controls, and the response was not affected by the use of prednisone or DMARDs.
Journal ArticleDOI
Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response
S. Oren,Michal Mandelboim,Yolanda Braun-Moscovici,Daphna Paran,Jacob N. Ablin,Irina Litinsky,D Comaneshter,David Levartovsky,Ella Mendelson,R Azar,Irena Wigler,Alexandra Balbir-Gurman,Dan Caspi,Ori Elkayam +13 more
TL;DR: Influenza virus vaccine generated a humoral response in all study patients with RA and controls, and treatment with rituximab does not preclude administration of vaccination against influenza.